The MALASSA project has officially kicked off. The project partners gathered in Amsterdam for the kick-off meeting to plan their joint work for the years ahead. We are delighted to be part of this international consortium.
What is MALASSA about?
The project aims to develop a new antibody therapy against Lassa fever. Lassa fever is an acute viral infectious disease and a hemorrhagic fever that occurs mainly in parts of West Africa. At the same time, MALASSA aims to help Europe be better prepared for pathogens like this one.
NovoArc’s contribution
NovoArc uses its unique lipids to produce tiny lipid nanoparticles. Building on this, we aim to develop a platform that enables antibodies to be produced faster, more flexibly and at larger scale, potentially saving both time and costs in manufacturing.
Within our team, Jana Kubackova is driving this work.
The consortium
We look forward to working with strong partners: Amsterdam UMC, MAbSilico, InSilicoTrials, PENTA Foundation, Polymun Scientific Immunbiologische Forschung GmbH, CEA, ERINHA, Inserm BSL4, AEFUTHA and Vaccinopolis.






